Mar 30, 2021

Dittmar has over 20 years of experience in the biotechnology sector with direct operating experience in the US, Europe and the Middle East, the venture capital company said. She served in multiple roles of increasing responsibility in the areas of corporate and business development with IDEC Pharmaceuticals, Biogen Inc., Dance Biopharm (now Aerami Therapeutics), and most recently Ethris GmbH, where she was appointed chief executive from 2018 to 2020. from Occidental College, and has authored primary research in the areas of immunology and lymphocyte signalling. "I am delighted to welcome Gita to the team,” said Naseem Amin, executive chairman of Arix, in a release. “Her experience in evaluating and executing late-stage investments for Pharmaceutical companies on the corporate development side, coupled with her expertise in early-stage company building, will be of great benefit to Arix's Investment team as we continue to build and support our existing investments and leverage our extensive pipeline of new opportunities in both early and late-stage assets." Quick facts: Arix Bioscience PLC Price: 190.8 GBX